Kaposi Sarcoma Market: Snapshot
Kaposi sarcoma (KS) refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes. The cancer usually appears as tumors on mucosal surfaces or on the skin, but can also develop in body parts such as the digestive tract, or the lungs. The abnormal KS cells cause brown, purple, or red blotches on the skin, called lesions.
The global Kaposi sarcoma market features a rising number of regional vendors commanding prominent shares in their respective regional territories. Owing to the looming patent expiries of several blockbuster drugs, the market is expected to witness the entry of several new companies producing generics. The situation also presents immense growth opportunities for leading companies with new drug formulations in the next few years.
Transparency Market Research states that the global Kaposi sarcoma market will exhibit a modest 2.2% CAGR over the period between 2016 and 2024, rising from a valuation of US$118.5 mn in 2015 to US$143.2 mn by 2024.
Obtain Report Details: http://www.transparencymarketresearch.com/kaposis-sarcoma-market.html
Chemotherapy Continues to Remain Most Preferred Course of Treatment despite High Cost
The key treatment methods for Kaposi sarcoma include immunotherapy, chemotherapy, and antiretroviral therapy. Of these, the segment of antiretroviral therapy emerged at the leading segment owing to the high incidence rate of AIDS-related Kaposi sarcoma. The segment will continue to grow at an encouraging pace in the next few years as well.
Over the report’s forecast period, however, the segment of chemotherapy is expected to exhibit growth at the most promising pace, chiefly owing to the high treatment cost and the high preference given to the treatment method by immunocompetent patients. Some of the most popular chemotherapy drugs in the market are vincristine, docetaxel, paclitaxel, bleomicin, daunorubicin, and liposomal doxorubicin. Although the high preference to this treatment method, its high cost could emerge as a key deterrent to patient population across some regions, especially across developing and less developed economies across Asia Pacific and Africa, limiting its growth prospects.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3354
North America to Retain Dominance in Global Market despite a Low Rate of Prevalence of Kaposi Sarcoma
From a geographical standpoint, North America is presently the leading contributor of revenue to the global Kaposi sarcoma market. The region holds a leading position in the global market owing to the presence of some of the world’s leading vendors in the field and the rising costs of drugs. The North America market for Kaposi sarcoma also benefits from the high rate of diagnosis of the condition and the easy availability of drugs. The region features a low incidence rate of the disease but has been witnessing a shortage in supply of drugs required for its treatment, leading to a wide demand-supply gap and subsequently significant scope of growth.
Over the report’s forecast period, the market is expected to witness the most promising rate of growth in the Middle East and Africa region. The region is expected to lead to the heightened demand for Kaposi sarcoma drugs owing to the high rate of incidence of the disease. The high rate of prevalence of HIV/AIDS is and thus the increased prevalence of AIDS induced Kaposi sarcoma in Eastern Africa is also a key driving factor, along with the fact that awareness among people is low.
Some of the leading players operating in the immensely consolidated vendor landscape of the global Kaposi sarcoma market are Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453
Global Cardiac Rhythm Management (CRM) Devices Batteries Market: Improved Power Sources Ensure Swift Uptake, says TMR
Global Cardiac Rhythm Management (CRM) Devices Batteries Market: Snapshot
As the availability of safer and cheaper lithium batteries is increasing, the global market for cardiac rhythm management (CRM) devices batteries is likely to attain new heights. CRM devices are designed to improve the health of patients with either too fast or too slow heartbeats. These devices are placed in the chests of patients suffering from arrhythmias or irregular heart rhythms. When a patient suffers from arrhythmias for too long, his/her heart cannot pump enough blood to the body, resulting in emergency situations, and even death. As these devices are powered by batteries, the demand for these devices will reflect in increased demand for these batteries.
According to the findings of Transparency Market Research (TMR), the global market for CRM devices batteries was valued at US$397.3 mn in 2015. The market is expected to expand at a CAGR of 3.0% between 2015 and 2024, reaching US$518.4 mn towards the end of 2024.
North America, Asia Pacific to Emerge as Key Markets
North America holds a strong position in the market presently, by virtue of its highly developed healthcare infrastructure and greater incidence of arrhythmias. The rising number of CRM implants is the prominent factor boosting the market for CRM devices batteries in this region. According to the findings of the U.S. CDC, nearly 750,000 hospitalizations each year in the U.S. are attributed to atrial fibrillation, the most common form of arrhythmia. The mortality rate associated with this condition was 130,000 deaths every year. The 2014 study also highlighted that as many as 2.7 to 6.1 million American citizens had atrial fibrillation. As a result, the number of CRM devices implants are slated to increase even further.
Asia Pacific is another region with great potential. The increasing healthcare expenditures of governments, growing per capita incomes of the middle class, and high prevalence of heart diseases, and growing awareness about heart diseases has been driving the market in Asia Pacific. Moreover, the development of highly efficient, technologically advanced CRM devices has been scooping out more demand. The increasing prevalence of cardiovascular diseases and sudden cardiac arrests will ensure that the demand for these products will continue to grow in China and India.
Technological Advancements to Ensure Greater Demand for ICDs and ICPs
Based on product type, the global market for CRM devices batteries has been segmented into cardiac resynchronization therapy devices, implantable cardiac pacemakers, and implantable cardioverter defibrillator. Implantable cardioverter defibrillator (ICD) is a device that records the heart rate of patients. The ICD is connected to the chambers of heart via two thin wires. As the heart beats, electric signals are sent to the ICD. As soon as an abnormal heartbeat is detected by this device, it aids the heart restore its normal pace. Cardiac defibrillation uses an electric shock to do this.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17678
An implantable cardiac pacemaker (ICP), on the other hand, is a small device that assists the heart to produce more regular heartbeats with the help of a small electric stimulation. Both of these devices are typically placed under the skin of chest, below the collarbone. A cardiac resynchronization therapy device can be a half-dollar sized pacemaker that ‘resynchronizes’ the heart. As these devices improve the blood flow and efficiency of the heart, several heart patients suffering with moderate to severe symptoms are using these devices.
The efforts of ongoing research and development projects will come to fruition, producing next-generation CRM devices with efficient batteries. The batteries used in the aforementioned devices are expected to undergo significant transformations and upgrading, thereby accelerating demand.
Some of the major companies operating in the global market for CRM devices batteries are EaglePicher Technologies, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, Greatbatch, Inc. (Integer), Quallion LLC, Medtronic, and St. Jude Medical, Inc.
Erdosteine is an oral mucolytic agent used for treatment of chronic obstructive bronchitis. Erdosteine is also used for treatment of acute and chronic bronchitis. It is an orphan drug. Erdosteine stimulates mucus production and increases mucociliary transport, which improves expectoration. It consists of two sulfhydryl groups freed after metabolic transformation in the liver. These released sulfhydryl groups help to break the disulphide bonds. This makes bronchial secretions more fluid and enhances elimination. Erdosteine shows inhibitory activity against the effects of free radicals produced by cigarette smoke. Pharmacokinetically, it acts by absorption, distribution, metabolism, and excretion. The elimination half-life of Erdosteine is about 1.46 hr. Adverse events of Erdosteine are quite low, and generally mild. It has been clinically proven that Erdosteine has good gastric tolerability after oral administration, and does not cause reflux phenomena like other thiols derivatives. Erdosteine has no direct effect on gastric mucus.
Read Full Report: http://www.transparencymarketresearch.com/erdosteine-market.html
Increasing prevalence of respiratory diseases, rising geriatric population, rapid population growth, and environmental pollution due to industrialization are expected to fuel the global erdosteine market. According to the WHO, chronic obstructive pulmonary disease (COPD) accounts for three million deaths globally each year and the number is expected to increase in the next few years. About 90% of chronic obstructive pulmonary disease (COPD) deaths occur in developing and underdeveloped countries. Rising research and development activities, increasing health care insurance coverage, and growing adoption for treatment options are the other factors driving the global erdosteine market. On the other hand, stringent regulations for product approval are likely to hamper the growth of the global erdosteine market. Erdosteine is used for rare diseases so maximum companies doing research and development which will increase the market competitiveness. Erdosteine is marketed in over 40 countries for the treatment of various respiratory diseases.
The erdosteine market has been segmented based on dosage form, age group, application, distribution channel, and region. In terms of dosage form, the market has been classified into capsules, dry suspension, dispersible tablets, and sachets. The capsule dosage form is highly used due to ease of use, availability in unit dosage form, and also easy in term of prescription scenario which will leads to less side effect. Based on age group, the erdosteine market has been segmented into adult and pediatric. In terms of application, the market has been classified into chronic obstructive pulmonary disease (COPD), acute bronchitis (AB), and chronic bronchitis (CB). Based on distribution channel, the erdosteine market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
In terms of region, the market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19166
North America dominated the erdosteine market due to rising geriatric population, early adoption of treatment procedures, and increasing prevalence of respiratory diseases. The geriatric population represents about 14.5% of the population of the U.S. According to the U.S. Department of Health and Human Service, the geriatric population will increase to 98 million by 2060, which is twice that in 2014. Europe is the second largest market for erdosteine attributed to increasing research and development activities and rising number of commercial licensing partnerships for erdosteine manufacturing. Asia Pacific is expected to grow at a higher rate driven by growing per capita expenditure, increasing health care insurance coverage, rapidly growing population, and rising per capita health care expenditure.
Major players operating in the erdosteine market include Edmond Pharma S.R.L., Alitair Pharmaceuticals, Manus Aktteva Biopharma LLP, Enaltec, Reine Life Science, Taj Pharmaceuticals Ltd., Recipharm AB, Glenmark Pharmaceuticals Ltd., Sigma-Aldrich Co. LLC, Genome Pharmaceuticals (Pvt.) Ltd., and Milan Pharma.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Global Non-Small Cell Lung Cancer Therapeutics Market to Reach US$15.1 bn by 2023, Asia Pacific to Report Fastest CAGR
Non-Small Cell Lung Cancer Therapeutics Market: Snapshot
Non-small cell lung cancer (NSCLC) is the one of the commonest form of lung cancers. It is the most feared too. This is because it metastasizes into the bones and other tissues, making it tough to diagnose and treat it. In fact, almost 90% of all lung cancer cases are non-small cell lung cancer. Drugs meant to treat such a type of cancer range from regular regimens to targeted therapies. They are formulated leveraging simple chemistries to advanced complex proteins. The global market for non-small cell lung cancer therapeutics has seen robust growth due to the strong awareness among people about it. Another factor majorly contributing to the market is favorable government initiatives. Further, rapid approvals for drugs for non-small cell lung cancer by regulatory bodies and generous monetary assistance for research has also filliped the market.
Despite the efficacy of targeted therapies and the uncovering of numerous molecular targets, the development of most drugs is in an early-stage pipeline. This, coupled with resistance to targeted therapies, is a major cause of worry in the non-small cell lung cancer therapeutics market.
The global non-small cell lung cancer therapeutics market was worth US$4.9 bn in 2014. Expanding at a CAGR of 12.1% from 2015 to 2023, it is slated to achieve a value of US$15.1 bn in 2023. The global non-small cell lung cancer therapeutics market is a fragmented with robust competition among the existing players that are both generic and branded companies. Some of the prominent names operating in the market are Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Inc., AstraZeneca plc, and Novartis AG.
Burgeoning Population to Propel Market in Asia Pacific
The global market for non-small cell lung cancer therapeutics comprises five key regions: North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America leads with maximum share in market on account of the presence of a superior healthcare infrastructure and strong support by the U.S. federal government. In terms of growth rate, however, Asia Pacific is predicted to outshine all other regions owing to the burgeoning population, growing awareness about non-small cell lung cancer, increasing number of government projects pertaining to lung cancer, and ongoing efforts for timely intervention.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504
Effectiveness of Angiogenesis Inhibitor Drives Growth
The global market for non-small cell lung cancer therapeutics market can be segmented on the basis of drugs into EGFR inhibitor, angiogenesis inhibitor, microtubule stabilizer, kinase inhibitor, folate antimetabolites, and PD-1/PD-L1 inhibitor. At present angiogenesis inhibitor, also known as anti-angiogenics that thwart formation of new blood vessels, dominates the market. Going forward too, it is likely to retain its leading position because of the strong demand for this efficacious, targeted therapy in the crucial Europe, Japan, and the U.S. markets. Avastin, a type of angiogenesis inhibitor, is predicted to see maximum uptake. Exhibiting a CAGR of 1.8% from 2015 to 2023, the angiogenesis inhibitor segment is predicted to attain a market value of US$ 2,020.4 mn by 2023.
The folate antimetabolites segment trails the angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments come in third and fourth positions in terms of market share. The PD-1/PD-L1 inhibitor will likely outpace all other segments vis-à-vis growth in the upcoming years due to the effectiveness of the treatment, which has been corroborated by clinical data that shows double survival rate. Unveiling of new targeted therapies with more surveillance rate could, however, hobble the growth in the market.
With the presence of a few but prominent players, such as Celgene, Roche, Novartis, and AbbVie, the global hematological malignancies market demonstrates an intensely competitive landscape. These four players collectively accounted for more than 58% of the overall market in 2015. Currently, they are focusing aggressively on expanding their distribution networks and geographical operations across Asia Pacific, Latin America, and the Middle East and Africa. Researchers expect the leading companies in this market to engage in mergers and acquisitions over the forthcoming years in a bid to bring about product differentiation to combat the competition.
As per the report, the global market for hematological malignancies offered an opportunity worth US$27.4 bn in 2015. Rising at a 7.50% CAGR between 2016 and 2024, this market is likely to increase to US$51.9 bn by the end of the forecast period. The prevalence of leukemia has been higher than lymphoma and myeloma. The trend is expected to remain so with the leukemia segment occupying nearly 50% of the overall market for hematological malignancies by 2024.
North America to Continue to Lead Global Hematological Malignancies Market
A regional analysis of the worldwide market for hematological malignancies has also been offered in this research report. According to the study, North America, the Middle East and Africa, Latin America, Europe, and Asia Pacific are the main regional markets for hematological malignancies across the world. In 2015, North America acquired the leading position in this market and was closely followed by Europe. The high prevalence of hematological cancers, together with state-of-art diagnostic technologies and increased awareness level of people, propelled the hematological malignancies significantly in both the regions.
Progressing at a CAGR of 6.80%, North America is likely to retain its leadership over the forecast period. The presence of an advanced healthcare infrastructure is likely to support this regional market to register a steady rise in the near future. Apart from this, the Asia Pacific market for hematological malignancies is also projected to witness strong growth over the next few years, owing to the existing rich pipeline and the imminent launch of targeted therapies during the forecast period, states the research report.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4580
Technological Advancements in Diagnostic Procedures to Positively Impact Demand
The sedentary and unhealthy lifestyle of people across the world has exposed them to a number of lifestyle-related diseases, hematological malignancies being a prominent one of them. The National Cancer Institute has stated that hematological cancer is the fifth most common cancer among people, globally, and is likely to record increased prevalence over the next few years. “With the upswing in the cases of hematological malignancies, the demand for their treatment is registering a tremendous rise, leading to a remarkable surge in the global market for hematological malignancies,” says an analyst at TMR.
In addition to this, the technological advancements in diagnostic procedures and the growing awareness level are projected to encourage people to go for diagnostic tests, which is likely to influence this market substantially in the near future. However, high costs of branded drugs and the absence of favorable reimbursement policies in emerging nations may hamper this market from growing steadily in the years to come, notes the study.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Hematological Malignancies Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”